Neurocrine Biosciences (NBIX) Capital Leases (2010 - 2017)

Neurocrine Biosciences (NBIX) has reported Capital Leases for 8 consecutive years, with $544000.0 the latest figure, recorded in Q1 2017.

• For the quarter ending Q1 2017, Capital Leases fell 32.76% year-over-year to $544000.0; the trailing twelve-month figure through Mar 2017 stood at $544000.0 (down 32.76% YoY), and the FY2016 full-year result was $617000.0, down 60.32% from the prior year.
• Capital Leases slipped to $544000.0 in Q1 2017 per NBIX's latest filing, from $617000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $3.0 million in Q1 2013 and bottomed at $544000.0 in Q1 2017.
• Historically, Capital Leases has averaged $1.8 million across 5 years, with a median of $2.1 million in 2015.
• The sharpest annual moves came in 2013 and 2016: Capital Leases jumped 32.63% in 2013, then slumped 61.22% in 2016.
• Over 5 years, Capital Leases stood at $2.7 million in 2013, then slipped by 17.5% to $2.2 million in 2014, then decreased by 29.67% to $1.6 million in 2015, then plunged by 60.32% to $617000.0 in 2016, then retreated by 11.83% to $544000.0 in 2017.
• According to Business Quant data, Capital Leases over the past three periods registered $544000.0, $617000.0, and $649000.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.